Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

READ ALSO: 10 Most Promising Biotech Stocks According to Hedge Funds. The cell and gene therapy sector has faced significant investment challenges since the boom years of 2020 and 2021.

READ ALSO: 10 Most Promising Biotech Stocks According to Hedge Funds. The cell and gene therapy sector has faced significant investment challenges since the boom years of 2020 and 2021.

Beam Therapeutics (BEAM) stock falls as patient dies after receiving the company's gene editing therapy.in an early-stage ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

The cell and gene therapy sector has faced significant investment ... our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds.

The cell and gene therapy sector has faced significant investment ... our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds.

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...

READ ALSO: 10 Most Promising Biotech Stocks According to Hedge Funds. The cell and gene therapy sector has faced significant investment challenges since the boom years of 2020 and 2021. However, signs ...

Generation Bio has been steadily advancing its iqDNA and ctLNP technologies, with recent pre-clinical data presented at the European Society of Gene and Cell Therapy (ESGCT ... their cautious stance ...